Autologous Anti-B7-H3 CAR T Cells clinical trials
How each study uses Autologous Anti-B7-H3 CAR T Cells is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Autologous Anti-B7-H3 CAR T Cells studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- B7-H3CART
- 2
Studies by the year they started
4 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
Stanford University (2) · Second Affiliated Hospital of Guangzhou Medical University (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Autologous Anti-B7-H3 CAR T Cells.
- Jan 2027Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian TumorsPhase 1 · Stanford University
- Mar 2027B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma MultiformePhase 1 · Stanford University
Studies
Open first, then newest update. How each study uses Autologous Anti-B7-H3 CAR T Cells is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian TumorsRecruitingPhase 1Stanford UniversityNCT06646627Written as B7-H3CART
- EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast CancerRecruitingEarly Phase 1Second Affiliated Hospital of Guangzhou Medical UniversityNCT05341492Written as EGFR/B7H3 CAR-T
- B7-H3 CAR-T for Recurrent or Refractory GlioblastomaRecruitingPhase 1/2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04077866Written as B7-H3 CAR-T
- B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma MultiformeActive, not recruitingPhase 1Stanford UniversityNCT05474378Written as B7-H3CART